

1/18




FIG. 1A

2/18










FIG. 1B

3/18




FIG. 2

4/18




FIG. 3

5/18




FIG. 4




FIG. 5

7/18




FIG. 6A

8/18




FIG. 6B




FIG. 6C

9/18




FIG. 7A




FIG. 7B

10/18

agonist mode




FIG. 8A

antagonist mode (+ estrogen)




FIG. 8B

11/18


agonist mode

FIG. 8C


antagonist mode (+ estrogen)

FIG. 8D

12/18




FIG. 9




FIG. 10A




FIG. 10B




FIG. 11A




FIG. 11B

MCF7-cells:





FIG. 12A

MCF-7 cells:



ECC-1 cells:





FIG. 12B

16/18

**Treatment**

- + Control
- x Tam (oral, 100 mg/kg q.d.)
- ◇ Fulv (s.c., 100 mg/kg q.d.)
- ▽ OP-1074 (oral, 100 mg/kg b.i.d.)

FIG. 13A

17/18




FIG. 13B

18/18




FIG. 13C